<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="editorial" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2025.1623587</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Differential activation of cell death pathways in macrophages as a result of adaptation to divergent microenvironment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Guzik</surname>
<given-names>Krzysztof</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref> <xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/397152/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Saas</surname>
<given-names>Philippe</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref> <xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/50651/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Masson</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref> <xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/700455/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University</institution>, <addr-line>Krak&#xf3;w</addr-line>, <country>Poland</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Universit&#xe9; Grenoble Alpes, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale (INSERM) U1209, CNRS Unit&#xe9; Mixte de Recherche (UMR) 5309, Institut pour l&#x2019;Avanc&#xe9;e des Biosciences (IAB), DIMAC</institution>, <addr-line>Grenoble</addr-line>, <country>France</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Etablissement Fran&#xe7;ais du Sang Auvergne-Rh&#xf4;ne-Alpes, R&amp;D Laboratory</institution>, <addr-line>Grenoble</addr-line>, <country>France</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Center for Translational and Molecular Medicine (CTM), Unit&#xe9; Mixte de Recherche (UMR) 1231, Universit&#xe9; Bourgogne Europe, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale (INSERM)</institution>, <addr-line>Dijon</addr-line>, <country>France</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Laboratoire de Biochimie, CHU Dijon</institution>, <addr-line>Dijon</addr-line>, <country>France</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited and Reviewed by: Pietro Ghezzi, Brighton and Sussex Medical School, United Kingdom</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Krzysztof Guzik, <email xlink:href="mailto:krzysztof.guzik@uj.edu.pl">krzysztof.guzik@uj.edu.pl</email>; Philippe Saas, <email xlink:href="mailto:Philippe.saas@efs.sante.fr">Philippe.saas@efs.sante.fr</email>; David Masson, <email xlink:href="mailto:david.masson@chu-dijon.fr">david.masson@chu-dijon.fr</email>
</p>
</fn>
<fn fn-type="other" id="fn003">
<p>&#x2020;ORCID: Krzysztof Guzik, <uri xlink:href="https://orcid.org/0000-0002-8794-0614">orcid.org/0000-0002-8794-0614</uri>; Philippe Saas, <uri xlink:href="https://orcid.org/0000-0002-8857-9939">orcid.org/0000-0002-8857-9939</uri>; David Masson, <uri xlink:href="https://orcid.org/0000-0003-1692-0699">orcid.org/0000-0003-1692-0699</uri>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>05</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1623587</elocation-id>
<history>
<date date-type="received">
<day>06</day>
<month>05</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>05</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Guzik, Saas and Masson</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Guzik, Saas and Masson</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" journal-id="Front Immunol" journal-id-type="nlm-ta" xlink:href="https://www.frontiersin.org/research-topics/49794/differential-activation-of-cell-death-pathways-in-macrophages-as-a-result-of-adaptation-to-divergent-microenvironment" ext-link-type="uri">Editorial on the Research Topic <article-title>Differential activation of cell death pathways in macrophages as a result of adaptation to divergent microenvironment</article-title>
</related-article>
<kwd-group>
<kwd>macrophage plasticity</kwd>
<kwd>regulated cell death</kwd>
<kwd>microenvironmental adaptation</kwd>
<kwd>inflammation</kwd>
<kwd>single-cell transcriptomics</kwd>
<kwd>ferroptosis</kwd>
<kwd>atherosclerosis</kwd>
<kwd>macrophage</kwd>
</kwd-group>
<contract-num rid="cn001">ANR-11 LABX-0021</contract-num>
<contract-sponsor id="cn001">Agence Nationale de la Recherche<named-content content-type="fundref-id">10.13039/501100001665</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Conseil r&#xe9;gional de Bourgogne-Franche-Comt&#xe9;<named-content content-type="fundref-id">10.13039/501100011773</named-content>
</contract-sponsor>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="7"/>
<page-count count="3"/>
<word-count count="855"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Inflammation</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Macrophages are ubiquitous immune cells residing within tissues, where they play critical roles in recognizing, engulfing, and processing foreign particles, dead cells, and debris. They are highly plastic, rapidly adapting their phenotype and functions in response to local microenvironmental signals (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). This plasticity extends to their cell death modalities: while apoptosis typically resolves inflammation and promotes tolerance as well as tissue repair, necroptosis, pyroptosis, and ferroptosis are associated with inflammatory responses of varying intensity (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Recent advances, notably single-cell technologies, have revealed that the expression and activation of cell death machinery within macrophages are highly context-dependent. Therefore, macrophage death is increasingly recognized as not merely a consequence of injury or dysfunction but also as an active effector mechanism shaping tissue homeostasis and pathologies, as exemplified in atherosclerosis (<xref ref-type="bibr" rid="B5">5</xref>&#x2013;<xref ref-type="bibr" rid="B7">7</xref>). This Research Topic aimed to explore the hypothesis that microenvironmental cues modulate the propensity of macrophages to undergo specific cell death pathways, impacting their protective or pathogenic roles across a wide range of diseases. The collected contributions shed light on the diversity of macrophage death responses under various pathological conditions, with a focus on cardiovascular, metabolic, and inflammatory diseases.</p>
</sec>
<sec id="s2">
<title>Summary of contributions</title>
<sec id="s2_1">
<title>Macrophage death in atherosclerosis</title>
<p>Several contributions highlighted how microenvironmental factors within atherosclerotic plaques influence macrophage death. In the study by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1513637">Pilot et&#xa0;al.</ext-link>, the inhibition of caspase-8 in macrophages shifted cell death from apoptosis to necroptosis. Despite reduced systemic inflammation, this switch led to larger necrotic cores and aggravated plaque burden, underlining the critical role of regulated cell death pathways in plaque stability. The work on Nrf2-deficient macrophages by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2023.1249379">Sarad et&#xa0;al.</ext-link> revealed how the loss of this antioxidant transcription factor in aortic macrophages promotes an inflammatory phenotype and alters the expression of death-related genes. Single-cell transcriptomic profiling identified specific subpopulations with enhanced susceptibility to ferroptosis and DNA damage, suggesting that iron homeostasis and oxidative stress are pivotal modulators of macrophage death in early atherogenesis. In a comprehensive review, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2023.1215612">Neels et&#xa0;al.</ext-link>, examined the interplay between macrophage death and plaque calcification. Beyond the failure of efferocytosis, apoptotic bodies and other cell death forms such as necroptosis and pyroptosis were shown to act as nucleation sites for calcium phosphate deposition, contributing to plaque instability.</p>
</sec>
<sec id="s2_2">
<title>Macrophage adaptation in other pathologies</title>
<p>Other contributions expanded this theme of macrophage death in other pathological settings. In diabetic cardiomyopathy, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2024.1393392">Zhang et&#xa0;al.</ext-link> reviewed the role of macrophages in the progression of cardiac dysfunction. They emphasized how prolonged exposure to metabolic stress reshapes macrophage phenotypes and potentially their death responses, highlighting emerging therapeutic avenues targeting macrophage plasticity. Using a model of radiation-induced heart injury, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2024.1363278">Cao et&#xa0;al.</ext-link> performed single-cell RNA sequencing to track macrophage dynamics during early tissue damage and repair. They identified stage-specific macrophage subsets with distinct death and survival profiles, suggesting that macrophage plasticity in the injured heart is tightly orchestrated to balance inflammation and tissue remodeling.</p>
</sec>
<sec id="s2_3">
<title>Mechanistic insights into macrophage cell death</title>
<p>At the mechanistic level, the study of HV1 proton channel inhibition by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2024.1487578">Kovacs et&#xa0;al.</ext-link> demonstrated how interference with proton homeostasis in macrophages leads to pH imbalance, ceramide accumulation, and reduced viability in a polarization-dependent manner. These findings underscore how ion channel regulation intricately connects to macrophage survival and death, particularly in inflammatory contexts. Finally, a review on the interplay between pyroptosis, necroptosis, and ferroptosis by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2024.1330461">Makuch et&#xa0;al.</ext-link> synthesizes current knowledge on the interdependence of these pathways. The authors proposed that macrophages dynamically balance different forms of regulated cell death in response to microenvironmental challenges, shaping outcomes in diseases such as atherosclerosis and cancer. Macrophage death is the ultimate effector mechanism responding to distinct stimuli of the microenvironment. Different types of necrotic death exhibit diverse dynamics and are differently controlled. The manuscripts of <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1513637">Pilot et&#xa0;al.</ext-link>, and <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2024.1330461">Makuch et&#xa0;al.</ext-link> illustrate this differential feature of necroptosis and ferroptosis. In an oxidized low-density lipoprotein-rich environment, inhibition of caspase-8 promotes necroptosis. Whereas in a Fe<sup>2+</sup>-rich environment, the Fenton reaction triggers macrophage ferroptosis. The Fenton reaction occurs with a rapid rate&#x2014;typical for inorganic chemistry&#x2014;and is not biologically controlled in contrast to caspase-8 activity. Only the instantaneous balance between hydroxyl radicals and intracellular antioxidants determines macrophage ferroptosis or survival.</p>
</sec>
<sec id="s2_4">
<title>Conclusion and Perspectives</title>
<p>Overall, the contributions to this Research Topic illustrate the remarkable sensitivity of macrophages to their tissue environment, particularly regarding the activation of death pathways. The modulation of macrophage death by environmental factors not only affects local immune responses but also plays a decisive role in disease progression and tissue integrity. Future research should aim to better characterize macrophage subsets that are prone to specific types of death, identify molecular signatures associated with these processes, and develop therapeutic strategies targeting macrophage death or survival in a disease-specific manner. Understanding macrophage death as an active and regulated phenomenon opens new possibilities for therapeutic innovation across many fields. Finally, several important themes emerge: the role of controlled apoptosis in preserving tissue integrity; the damaging effects of inflammatory forms of death like necroptosis and ferroptosis; and the importance of redox signaling, ion homeostasis, and epigenetic mechanisms in determining macrophage fate.</p>
</sec>
</sec>
</body>
<back>
<sec id="s3" sec-type="author-contributions">
<title>Author contributions</title>
<p>KG: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. PS: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. DM: Writing &#x2013; review &amp; editing, Writing &#x2013; original draft.</p>
</sec>
<sec id="s4" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Agence Nationale de la Recherche (ANR-11 LABX-0021 (Labex Lipstic); ANR-19-CE14-0020 (PRC PUMAs); the University Hospital of Dijon Bourgogne and by grants from the Conseil R&#xe9;gional de Bourgogne Franche-Comt&#xe9;.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We would like to thank all the authors for their contribution to this Research Topic and all peer reviewers for their insightful comments.</p>
</ack>
<sec id="s5" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>Author PS is the author of a patent and a shareholder of the company Med&#x2019;Inn&#x2019;Pharma.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec id="s6" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec id="s7" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Silvin</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ginhoux</surname> <given-names>F</given-names>
</name>
<name>
<surname>Merad</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Macrophages in health and disease</article-title>. <source>Cell</source>. (<year>2022</year>) <volume>185</volume>:<page-range>4259&#x2013;79</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2022.10.007</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname> <given-names>RY</given-names>
</name>
<name>
<surname>Black</surname> <given-names>A</given-names>
</name>
<name>
<surname>Qian</surname> <given-names>BZ</given-names>
</name>
</person-group>. <article-title>Macrophage diversity in cancer revisited in the era of single-cell omics</article-title>. <source>Trends Immunol</source>. (<year>2022</year>) <volume>43</volume>:<page-range>546&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.it.2022.04.008</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robinson</surname> <given-names>N</given-names>
</name>
<name>
<surname>Ganesan</surname> <given-names>R</given-names>
</name>
<name>
<surname>Heged&#x171;s</surname> <given-names>C</given-names>
</name>
<name>
<surname>Kov&#xe1;cs</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kufer</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Vir&#xe1;g</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Programmed necrotic cell death of macrophages: Focus on pyroptosis, necroptosis, and parthanatos</article-title>. <source>Redox Biol</source>. (<year>2019</year>) <volume>26</volume>:<elocation-id>101239</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.redox.2019.101239</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newton</surname> <given-names>K</given-names>
</name>
<name>
<surname>Dixit</surname> <given-names>VM</given-names>
</name>
<name>
<surname>Kayagaki</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Dying cells fan the flames of inflammation</article-title>. <source>Science</source>. (<year>2021</year>) <volume>374</volume>:<page-range>1076&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.abi5934</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tabas</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>Macrophage death and defective inflammation resolution in atherosclerosis</article-title>. <source>Nat Rev Immunol</source>. (<year>2010</year>) <volume>10</volume>:<fpage>36</fpage>&#x2013;<lpage>46</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri2675</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nogie&#x107;</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bzowska</surname> <given-names>M</given-names>
</name>
<name>
<surname>Demczuk</surname> <given-names>A</given-names>
</name>
<name>
<surname>Varol</surname> <given-names>C</given-names>
</name>
<name>
<surname>Guzik</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Phenotype and response to PAMPs of human monocyte-derived foam cells obtained by long-term culture in the presence of oxLDLs</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>1592</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.01592</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Meyer</surname> <given-names>GRY</given-names>
</name>
<name>
<surname>Zurek</surname> <given-names>M</given-names>
</name>
<name>
<surname>Puylaert</surname> <given-names>P</given-names>
</name>
<name>
<surname>Martinet</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets</article-title>. <source>Nat Rev Cardiol</source>. (<year>2024</year>) <volume>21</volume>:<page-range>312&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41569-023-00957-0</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>